OQ Chemicals has launched a new pilot plant for customized esters in Oberhausen, Germany. The new plant will help the firm to produce small quantities of esters for test purposes which can later on be produced on a large-scale.

Ineos Olefins & Polymer Europe has entered into a renewable power agreement with Skagerak Energitjenester under which the firm will supply 100 % green energy to Ineos’ Rafnes and Bamble plants in Norway.

Under an agreement signed between Veolia and Lyondell Basell, Veolia will sell its 50 % stake in the joint venture Quality Circular Polymers (QCP) to Lyondell Basell who will then become 100 % owner of the joint venture.

With an aim to support the growing polymer industry in China, Nouryon intends to expand its capacity of organic peroxide at its Ningbo plant in the country. Organic peroxides can be used to improve the properties of recycled polypropylene.

Trinseo’s new pilot facility was inaugurated in April in which the dissolution technology helps to extract 100 % recycled PC for use in new materials. Jo-Annes de Bat, Provincial Executive of the Netherlands was the guest of honor at the inauguration ceremony.

With the acquisition of the contract manufacturing company ADL Biopharma, Wacker will strengthen its biotechnology business. The purchase price for the acquisition of ADL Biopharma exceeds 100 million euros.

Under a partnership agreement between the two parties, Adnoc and Baker Hughes will speed up the development and commercialization of technology solutions for green and low-carbon hydrogen as well as graphene.

With a power rating of 25 MW and a capacity of 75 MWh, Total Energies has developed its largest battery energy storage project in Europe. Located at its Antwerp refinery, the project will help to meet the needs of the European and Belgian high-voltage transmission network.

BASF’s OASE blue technology will be used to recover CO2 from flue gas and Messer will then refine it up to food grade quality in order to supply the CO2 to its customers across Europe.

The rising demand of cell and gene therapies across the globe has forced life science, pharma companies and even research institutes to turn to Contract Development and Manufacturing Organizations (CDMOs) for developing and delivering treatments quickly to patients in need. Digital transformation is one area that is being explored by CDMOs to accelerate this pace.